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Luke Fletcher and John Michael Schmitt 
Biology, George Fox University, Newberg, OR 
 
Abstract 
Hormones and agonists that enhance cell survival through binding specific G Protein-
Coupled Receptors (GPCRs) are of particular interest in cancer cell survival. LNCaP cells 
have been shown to express muscarinic cholinergic receptors that are responsive to the 
agonist, carbachol. In addition, LNCaP cells specifically express the M3-subtype of 
GPCR’s that may couple carbachol to Gq, increases in intracellular calcium, and 
activation of the intracelluar Ca2+/calmodulin-dependent protein kinases (CaM Ks). The 
CaM Kinase family of proteins includes CaM KII, CaM Kinase Kinase (CaM KK) and its 
substrates CaM KIV, CaM KI and the protein kinase AKT. AKT is an anti-apoptotic enzyme 
that phosphorylates BAD and inhibits caspase activation. Our goals were to examine the 
mechanism of carbachol activation of AKT in LNCaP prostate cancer cells and evaluate 
whether CaM Ks may be mediating carbachol’s activation of AKT and cell survival in 
LNCaP cells. The results suggest that AKT phosphorylation was increased in response to 
a five-minute stimulation with 10µM carbachol in LNCaP cells which was blocked by the 
CaM K family inhibitor, KN-93 suggesting the involvement of the CaM Kinase proteins in 
the pathway. In contrast, there was no inhibition by the MEK inhibitor, U0126 
suggesting that AKT is activated independently of MEK and ERK. Interestingly, the CaM 
KK inhibitor, STO-609 potently inhibited cabachol’s activation of AKT. Furthermore, our 
results indicate that carbachol treatment of LNCaP cells promoted cell survival through 
CaM Ks. Carbachol’s survival effects also appear to be operating through the M3-
subtype of GPCRs, CaM KK, and its phosphorylation of AKT.  
